Navigation Links
Biological Product Shows Promise Against Gum Disease
Date:4/4/2009

When tested in rabbits, resolvins reduced inflammation ,,,,

SATURDAY, April 4 (HealthDay News) -- Resolvins, a new family of biologically active products of omega-3 fatty acids, may be able to remedy the inflammation of periodontal disease and restore gums to health, say Boston University researchers.

Two types of resolvins are made from the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), both of which keep blood triglycerides under control and may inhibit the progression of atherosclerosis. EPA and DHA help reduce inflammation and are often used to help people with inflammatory conditions such as rheumatoid arthritis and Crohn's disease, according to background information in a new release from the International & American Association for Dental Research.

Resolvins of the E series (RvE1) are derived from EPA, and resolvins of the D series (RvD1) are derived from DHA. Previous research showed that RvE1 provided protection against soft tissue and bone loss associated with gum disease and actually restored lost soft tissue and bone to healthy levels.

In this new study, the researchers caused gum disease in rabbits by applying P. gingivalis, the bacteria that causes gum disease in humans. Treatment with RvD1 was beneficial.

The study was to be presented Saturday at the research association's meeting in Miami.

The finding supports the researchers' hypothesis that DHA-derived resolvins, as well as those derived from EPA, have the potential to resolve inflammation and restore periodontal health, the association said in its news release.

More information

The American Academy of Periodontology has more about gum disease.



-- Robert Preidt



SOURCE: International & American Association for Dental Research, news release, April 4, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Thomson Scientific Announces BONDplus for Biological Researchers
2. Neurobiological Technologies Reports Going Concern Qualification
3. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
4. Study questions assumptions about human sensitivity to biological motion
5. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
6. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
7. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
8. Biological markers of prostate cancer shed light on cancer burden faced by African-American men
9. Sanofi Pasteur Enters Agreement With Crucell for Next-Generation Biologicals Against Rabies
10. Biological Link Between BRCA1 and Breast Cancer Detailed
11. Boston IVF is First in Northeast to Offer Pioneering Test of Womens Biological Clock
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Biological Product Shows Promise Against Gum Disease
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced its strategic partnership with Connance, a healthcare industry leader providing predictive ... proven, proprietary technology combine to provide health systems, hospitals and ambulatory surgical ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
Breaking Medicine Technology: